Updates related to EBM catalogue in Germany

10

Oct 2019

The fee negotiations for the coming year are over - the National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) agreed on an increase in the monetary conversion factor for all medical and psychotherapeutic services in the amount of 1.52 percent.

From the coming year, the monetary conversion factor is 10.9871 cents (currently it amounts to 10.8226 cents). The increase corresponds to a rise in fees of around 565 million euros. The monetary conversion factor determines the prices of the medical and psychotherapeutic services and is renegotiated every year.

GKV-Spitzenverband and KBV have also agreed to sponsor the video consultations. From 1 October 2019, the statutory health insurance companies will pay start-up funding for doctors who conduct video consultation sessions up to €500 per doctor and quarter. The funding opportunity is valid for two years and takes place as a surcharge on the fee order item (GOP) 01451 (rating: 92 points / €9.95). Further adjustments in terms of promotion of the video consultations are planned to be agreed by the Evaluation Committee by the end of September.

Beginning from the next year, in the field of human genetics, the medical assessment services and consulting services (GOP 01841, 11230, 11233 to 11236) will be excluded from the morbidity-based overall remuneration (morbiditätsbedingen Gesamtvergütung, MGV) and reimbursed extrabudgetary - initially for three years. The background is the volume growth in this area.

GKV-Spitzenverband and KBV also agreed that existing extrabudgetary remuneration for in-vitro diagnostic of tumor genetic alterations (EBM Section 19.4.2) would be provided outside MGV until July 1, 2023. Thus, the evaluation committee takes into account the growing importance of genetic diagnostics and counseling. This benefit in particular patients with rare diseases and malignant neoplasms.

The regional change rates in morbidity and demographics were decided by KBV and GKV-Spitzenverband in the first round of fee negotiations on the 14th of August. Together with the monetary conversion factor, they form the basis for the regional remuneration negotiations, which begin in the autumn.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more